DDInter1620 DDInter1802
Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011.
Ropivacaine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ticagrelor
Ropivacaine {u} (Compound) causes {v} (Side Effect) Cough
Cough {u} (Side Effect) is caused by {v} (Compound) Ticagrelor
Ropivacaine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Nifedipine
Nifedipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Ropivacaine {u} (Compound) causes {v} (Side Effect) Cough
Cough {u} (Side Effect) is caused by {v} (Compound) Nifedipine
Nifedipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Ropivacaine {u} (Compound) resembles {v} (Compound) Lidocaine
Lidocaine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ticagrelor
Ropivacaine {u} (Compound) causes {v} (Side Effect) Oliguria
Oliguria {u} (Side Effect) is caused by {v} (Compound) Hydromorphone
Hydromorphone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Ropivacaine {u} (Compound) resembles {v} (Compound) Lidocaine
Lidocaine {u} (Compound) palliates {v} (Disease) coronary artery disease
coronary artery disease {u} (Disease) is treated by {v} (Compound) Ticagrelor
Ropivacaine {u} (Compound) resembles {v} (Compound) Bupivacaine
Bupivacaine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ticagrelor
Ropivacaine {u} (Compound) resembles {v} (Compound) Levobupivacaine
Levobupivacaine {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Ticagrelor
Ropivacaine {u} (Compound) causes {v} (Side Effect) Urethral disorder
Urethral disorder {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Ropivacaine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Ropivacaine (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Ticagrelor (Compound)
Ropivacaine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nifedipine (Compound) and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Ropivacaine (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Nifedipine (Compound) and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Ropivacaine (Compound) resembles Lidocaine (Compound) and Lidocaine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ticagrelor (Compound)
Ropivacaine (Compound) causes Oliguria (Side Effect) and Oliguria (Side Effect) is caused by Hydromorphone (Compound) and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Ropivacaine (Compound) resembles Lidocaine (Compound) and Lidocaine (Compound) palliates coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Ticagrelor (Compound)
Ropivacaine (Compound) resembles Bupivacaine (Compound) and Bupivacaine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Ropivacaine (Compound) resembles Levobupivacaine (Compound) and Levobupivacaine (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Ropivacaine (Compound) causes Urethral disorder (Side Effect) and Urethral disorder (Side Effect) is caused by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ticagrelor